Opportunistic Infections *ACPE-Accredited*

Opportunistic infections in HIV patients represent a critical clinical challenge, necessitating proactive management through antiretroviral therapy (ART) to restore immune function. CD4 cell count thresholds serve as primary indicators for initiating prophylaxis and treatment for infections like Pneumocystis pneumonia, Toxoplasmosis, Histoplasmosis, Cryptococcus, and Mycobacterium avium complex. Bactrim remains the first-line agent for Pneumocystis pneumonia, targeting fungal folate synthesis, while management of Toxoplasmosis requires avoiding environmental exposures like cat feces. Effective treatment protocols often involve combination therapies to mitigate drug resistance, particularly with macrolides in Mycobacterium avium complex infections. Clinicians must navigate complex drug-drug interactions and monitor for toxicities, such as electrolyte imbalances or hepatotoxicity, while tailoring interventions based on patient-specific CD4 counts and regional endemicity. These strategies ensure patient stabilization while ART works to rebuild the immune system and reduce long-term mortality risks.